Monteplase has been used in trials studying the treatment of Pulmonary Embolism.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Apixaban | Apixaban may increase the anticoagulant activities of Monteplase. |
| Dabigatran etexilate | Dabigatran etexilate may increase the anticoagulant activities of Monteplase. |
| Dasatinib | The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Monteplase. |
| Deferasirox | The risk or severity of gastrointestinal bleeding can be increased when Monteplase is combined with Deferasirox. |
| Ursodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Monteplase is combined with Ursodeoxycholic acid. |
| Glycochenodeoxycholic Acid | The risk or severity of bleeding and bruising can be increased when Monteplase is combined with Glycochenodeoxycholic Acid. |
| Cholic Acid | The risk or severity of bleeding and bruising can be increased when Monteplase is combined with Cholic Acid. |
| Glycocholic acid | The risk or severity of bleeding and bruising can be increased when Monteplase is combined with Glycocholic acid. |
| Deoxycholic acid | The risk or severity of bleeding and bruising can be increased when Monteplase is combined with Deoxycholic acid. |
| Taurocholic acid | The risk or severity of bleeding and bruising can be increased when Monteplase is combined with Taurocholic acid. |
| Obeticholic acid | The risk or severity of bleeding and bruising can be increased when Monteplase is combined with Obeticholic acid. |
| Chenodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Monteplase is combined with Chenodeoxycholic acid. |
| Taurochenodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Monteplase is combined with Taurochenodeoxycholic acid. |
| Tauroursodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Monteplase is combined with Tauroursodeoxycholic acid. |
| Bamet-UD2 | The risk or severity of bleeding and bruising can be increased when Monteplase is combined with Bamet-UD2. |
| Dehydrocholic acid | The risk or severity of bleeding and bruising can be increased when Monteplase is combined with Dehydrocholic acid. |
| Hyodeoxycholic Acid | The risk or severity of bleeding and bruising can be increased when Monteplase is combined with Hyodeoxycholic Acid. |
| Edoxaban | The risk or severity of bleeding can be increased when Edoxaban is combined with Monteplase. |
| Ibrutinib | The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Monteplase. |
| Obinutuzumab | The risk or severity of bleeding and hemorrhage can be increased when Monteplase is combined with Obinutuzumab. |
| Rivaroxaban | Monteplase may increase the anticoagulant activities of Rivaroxaban. |
| Sugammadex | The risk or severity of bleeding and hemorrhage can be increased when Monteplase is combined with Sugammadex. |
| Tibolone | Tibolone may increase the anticoagulant activities of Monteplase. |
| Tipranavir | The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Monteplase. |
| Urokinase | Urokinase may increase the anticoagulant activities of Monteplase. |
| Vitamin E | Vitamin E may increase the anticoagulant activities of Monteplase. |
| Vorapaxar | The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Monteplase. |
| Aprotinin | The therapeutic efficacy of Monteplase can be decreased when used in combination with Aprotinin. |
| Ginkgo biloba | Ginkgo biloba may increase the anticoagulant activities of Monteplase. |
| Ifosfamide | The risk or severity of bleeding can be increased when Ifosfamide is combined with Monteplase. |
| Quinine | The therapeutic efficacy of Monteplase can be increased when used in combination with Quinine. |
| Quinidine | The therapeutic efficacy of Monteplase can be increased when used in combination with Quinidine. |
| Tamoxifen | The risk or severity of bleeding can be increased when Tamoxifen is combined with Monteplase. |
| Toremifene | The risk or severity of bleeding can be increased when Toremifene is combined with Monteplase. |
| Pentoxifylline | The therapeutic efficacy of Monteplase can be increased when used in combination with Pentoxifylline. |
| Pentosan polysulfate | Pentosan polysulfate may increase the anticoagulant activities of Monteplase. |
| Levocarnitine | The therapeutic efficacy of Monteplase can be increased when used in combination with Levocarnitine. |
| Diethylstilbestrol | Diethylstilbestrol may decrease the anticoagulant activities of Monteplase. |
| Chlorotrianisene | Chlorotrianisene may decrease the anticoagulant activities of Monteplase. |
| Conjugated estrogens | Conjugated estrogens may decrease the anticoagulant activities of Monteplase. |
| Mestranol | The risk or severity of adverse effects can be increased when Mestranol is combined with Monteplase. |
| Estrone sulfate | Estrone sulfate may decrease the anticoagulant activities of Monteplase. |
| Quinestrol | Quinestrol may decrease the anticoagulant activities of Monteplase. |
| Hexestrol | Hexestrol may decrease the anticoagulant activities of Monteplase. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Monteplase. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Monteplase. |
| Polyestradiol phosphate | Polyestradiol phosphate may decrease the anticoagulant activities of Monteplase. |
| Esterified estrogens | Esterified estrogens may decrease the anticoagulant activities of Monteplase. |
| Zeranol | Zeranol may decrease the anticoagulant activities of Monteplase. |
| Equol | Equol may decrease the anticoagulant activities of Monteplase. |
| Methallenestril | Methallenestril may decrease the anticoagulant activities of Monteplase. |
| Epimestrol | Epimestrol may decrease the anticoagulant activities of Monteplase. |
| Moxestrol | Moxestrol may decrease the anticoagulant activities of Monteplase. |
| Estradiol acetate | Estradiol acetate may decrease the anticoagulant activities of Monteplase. |
| Estradiol benzoate | Estradiol benzoate may decrease the anticoagulant activities of Monteplase. |
| Estradiol cypionate | Estradiol cypionate may decrease the anticoagulant activities of Monteplase. |
| Estradiol valerate | Estradiol valerate may decrease the anticoagulant activities of Monteplase. |
| Biochanin A | Biochanin A may decrease the anticoagulant activities of Monteplase. |
| Formononetin | Formononetin may decrease the anticoagulant activities of Monteplase. |
| Estriol | Estriol may decrease the anticoagulant activities of Monteplase. |
| Icosapent | The risk or severity of bleeding and hemorrhage can be increased when Icosapent is combined with Monteplase. |
| Mesalazine | The risk or severity of bleeding can be increased when Mesalazine is combined with Monteplase. |
| Indomethacin | The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Monteplase. |
| Nabumetone | The risk or severity of bleeding and hemorrhage can be increased when Nabumetone is combined with Monteplase. |
| Ketorolac | The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Monteplase. |
| Tenoxicam | The risk or severity of bleeding and hemorrhage can be increased when Tenoxicam is combined with Monteplase. |
| Celecoxib | The risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Monteplase. |
| Tolmetin | The risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with Monteplase. |
| Rofecoxib | The risk or severity of bleeding and hemorrhage can be increased when Rofecoxib is combined with Monteplase. |
| Piroxicam | The risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with Monteplase. |
| Fenoprofen | The risk or severity of bleeding and hemorrhage can be increased when Fenoprofen is combined with Monteplase. |
| Valdecoxib | The risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with Monteplase. |
| Diclofenac | The risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Monteplase. |
| Sulindac | The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Monteplase. |
| Flurbiprofen | The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen is combined with Monteplase. |
| Etodolac | The risk or severity of bleeding and hemorrhage can be increased when Etodolac is combined with Monteplase. |
| Mefenamic acid | The risk or severity of bleeding and hemorrhage can be increased when Mefenamic acid is combined with Monteplase. |
| Naproxen | The risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Monteplase. |
| Sulfasalazine | The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with Monteplase. |
| Phenylbutazone | The risk or severity of bleeding and hemorrhage can be increased when Phenylbutazone is combined with Monteplase. |
| Meloxicam | The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Monteplase. |
| Carprofen | The risk or severity of bleeding and hemorrhage can be increased when Carprofen is combined with Monteplase. |
| Diflunisal | The risk or severity of bleeding and hemorrhage can be increased when Diflunisal is combined with Monteplase. |
| Salicylic acid | The risk or severity of bleeding and hemorrhage can be increased when Salicylic acid is combined with Monteplase. |
| Meclofenamic acid | The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with Monteplase. |
| Oxaprozin | The risk or severity of bleeding and hemorrhage can be increased when Oxaprozin is combined with Monteplase. |
| Ketoprofen | The risk or severity of bleeding and hemorrhage can be increased when Ketoprofen is combined with Monteplase. |
| Balsalazide | The risk or severity of bleeding and hemorrhage can be increased when Balsalazide is combined with Monteplase. |
| Olsalazine | The risk or severity of bleeding can be increased when Olsalazine is combined with Monteplase. |
| Lumiracoxib | The risk or severity of bleeding and hemorrhage can be increased when Lumiracoxib is combined with Monteplase. |
| Magnesium salicylate | The risk or severity of bleeding and hemorrhage can be increased when Magnesium salicylate is combined with Monteplase. |
| Salsalate | The risk or severity of bleeding and hemorrhage can be increased when Salsalate is combined with Monteplase. |
| Choline magnesium trisalicylate | The risk or severity of bleeding and hemorrhage can be increased when Choline magnesium trisalicylate is combined with Monteplase. |
| Antrafenine | The risk or severity of bleeding and hemorrhage can be increased when Antrafenine is combined with Monteplase. |
| Aminophenazone | The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Monteplase. |
| Antipyrine | The risk or severity of bleeding and hemorrhage can be increased when Antipyrine is combined with Monteplase. |
| Tiaprofenic acid | The risk or severity of bleeding and hemorrhage can be increased when Tiaprofenic acid is combined with Monteplase. |
| Etoricoxib | The risk or severity of bleeding and hemorrhage can be increased when Etoricoxib is combined with Monteplase. |
| Taxifolin | The risk or severity of bleeding and hemorrhage can be increased when Taxifolin is combined with Monteplase. |
| Oxyphenbutazone | The risk or severity of bleeding and hemorrhage can be increased when Oxyphenbutazone is combined with Monteplase. |